Russell Investments Group Ltd. Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Russell Investments Group Ltd. increased its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 539.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 53,282 shares of the biopharmaceutical company's stock after purchasing an additional 44,945 shares during the quarter. Russell Investments Group Ltd.'s holdings in Amicus Therapeutics were worth $502,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Amicus Therapeutics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company's stock valued at $275,619,000 after buying an additional 458,143 shares during the last quarter. Wellington Management Group LLP lifted its stake in Amicus Therapeutics by 18.8% in the fourth quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company's stock valued at $268,112,000 after buying an additional 4,497,950 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Amicus Therapeutics by 3.4% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,267,375 shares of the biopharmaceutical company's stock valued at $30,779,000 after buying an additional 107,348 shares during the last quarter. Norges Bank purchased a new stake in Amicus Therapeutics in the fourth quarter valued at approximately $29,033,000. Finally, Rice Hall James & Associates LLC lifted its stake in Amicus Therapeutics by 41.0% in the fourth quarter. Rice Hall James & Associates LLC now owns 1,371,080 shares of the biopharmaceutical company's stock valued at $12,916,000 after buying an additional 398,942 shares during the last quarter.

Analyst Ratings Changes

Several research firms have recently commented on FOLD. Cantor Fitzgerald restated an "overweight" rating and set a $21.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Needham & Company LLC reissued a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company lowered their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. Finally, StockNews.com lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, February 20th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, Amicus Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $16.75.

Amicus Therapeutics Trading Up 0.5 %

Shares of NASDAQ:FOLD traded up $0.04 during trading on Tuesday, reaching $7.43. The stock had a trading volume of 332,610 shares, compared to its average volume of 2,620,581. Amicus Therapeutics, Inc. has a fifty-two week low of $6.20 and a fifty-two week high of $12.65. The business has a fifty day moving average price of $8.11 and a 200-day moving average price of $9.37. The stock has a market cap of $2.28 billion, a P/E ratio of -41.31, a PEG ratio of 1.51 and a beta of 0.79. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.